Sandeep Jain has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandeep Jain, on behalf of himself, other promoters, promoter group members, and persons acting in concert of Panacea Biotec, has filed the annual declaration under Regulation 31(4) of SEBI's Takeover Regulations for the financial year ended March 31, 2025. The disclosure states that no encumbrance (pledge, lien, or mortgage) was created on any shares of the company during FY 2024-25, directly or indirectly. It further confirms that as of March 31, 2025, there is no encumbrance on any shares held by the promoters and promoter group, which includes 17 listed entities such as Dr. Rajesh Jain, Sandeep Jain, family members, HUFs, and partnership firms. This is a routine yearly compliance filing required from promoters.
This is a neutral, routine compliance filing. Shareholders can take comfort that the promoter group has not pledged any of their shares, indicating no immediate funding pressure or risk of forced selling from the promoter side. No direct impact on stock price is expected from this disclosure alone.